Insulin for Obesity

JL
Overseen ByJacqueline Limberg
Age: 18+
Sex: Any
Trial Phase: Phase < 1
Sponsor: University of Missouri-Columbia
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

Determine the impact of obesity with insulin resistance on the neurovascular response to brain insulin stimulation.

Are You a Good Fit for This Trial?

This trial is for adults aged 18-65 who are either healthy and normal weight (BMI 18-25) or have obesity with insulin resistance (BMI 30-45). Participants must not smoke, be pregnant, have major health issues like heart disease or diabetes, or recent large weight changes.

Inclusion Criteria

HOMA-IR <2
Healthy normal weight adults with BMI 18-25 kg/m2
Individuals with obesity and comorbid insulin resistance (IR) with BMI 30-45 kg/m2
See 4 more

Exclusion Criteria

Body weight change >10% within the last 6 months
Claustrophobia
Current smoking, tobacco, or nicotine use
See 11 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive human insulin (160 IU) administered using an intra-nasal device

1 day
1 visit (in-person)

Follow-up

Participants are monitored for changes in muscle sympathetic nerve activity, cerebral blood flow, and leg blood flow

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • human insulin

Trial Overview

The study tests how the body’s blood vessels respond to insulin in people with and without obesity-related insulin resistance. Human insulin is given to see its effects on brain and body blood flow.

How Is the Trial Designed?

2

Treatment groups

Experimental Treatment

Group I: Insulin (MRI)Experimental Treatment1 Intervention
Group II: Insulin (Doppler)Experimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Missouri-Columbia

Lead Sponsor

Trials
387
Recruited
629,000+